glp-1 oral receptor agonists are generating a great deal of excitement as a potential inflection point in diabetes and obesity care. Amid the enthusiasm, however, a quieter and clinically important issue is GLP-1 weight-loss drugs may also

Users running 2-3 cycles over 6 months typically report the most significant cumulative changes: 3-6% body fat reduction, improved muscle definition, and better overall body composition

Many individuals seek to achieve a deeper, more natural-looking tan without the need for excessive sun exposure or the use of artificial tanning products

Clinical studies indicate that the combination maintains physiological GH pulsatility and IGF-1 elevation, which may reduce side effects compared with direct HGH therapy

doi: 10.1007/s13205-021-02738-3 52 SebastiaoICandeiasESantosMSde OliveiraCRMoreiraPIDuarteAI

Abbreviations AUD: Alcohol Use Disorder CI: Confidence Interval DPP-4: Dipeptidyl Peptidase-4 DPP-4i: Dipeptidyl Peptidase-4 Inhibitor EMA: European Medicines Agency FDA: Food and Drug Administration GABA: Gamma-Aminobutyric Acid GLP-1: Glucagon-Like Peptide-1 GLP-1RA: Glucagon-Like Peptide-1 Receptor Agonist HR: Hazard Ratio I: I-squared Statistic ICD-10: International Classification of Diseases, 10th Revision NAc: Nucleus Accumbens NOS: NewcastleOttawa Scale NR: Not Reported PEth: Phosphatidylethanol PICOS: Population, Intervention, Comparison, Outcomes, Study Design PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses PROSPERO: International Prospective Register of Systematic Reviews Q: Cochrans Q Statistic RCT: Randomized Controlled Trial REML: Restricted Maximum Likelihood RYGB: Roux-en-Y Gastric Bypass SD: Standard Deviation SE: Standard Error T2DM: Type 2 Diabetes Mellitus : Tau-squared VTA: Ventral Tegmental Area References Carvalho AF, Heilig M, Perez A, Probst C, Rehm J